NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

Summary

This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective was to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).

Timeline

Start

2017-09-28

Primary completion

2019-12-31

Completion

2019-12-31

Outcome

Outcome not reported

Stopped: “Despite promising efficacy and a good tolerability profile in Part I, it was decided not to initiate Part II as the pre-specified boundary for efficacy was uncertain to be met in this heavily pre-treated population with significant co-morbidities”

Drugs

Indications